ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
New leadership team announced at NATHEALTH Annual General Meeting 2024
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
